Acute Myeloid Leukemia Clinical Trial

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Summary

This study is designed to assess the safety of Mylotarg therapy in routine practice.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Treated by Mylotarg
Provide ICF

Study is for people with:

Acute Myeloid Leukemia

Estimated Enrollment:

500

Study ID:

NCT00161668

Recruitment Status:

Completed

Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 58 Locations for this study

See Locations Near You


Tucson Arizona, 85404, United States

Berkely California, 94704, United States

Burbank California, 91505, United States

Concord California, 94520, United States

Loma Linda California, 92354, United States

Los Angeles California, 90095, United States

San Francisco California, 94143, United States

Sylmar California, 91342, United States

Denver Colorado, 80218, United States

Boynton Beach Florida, 33435, United States

Plantation Florida, 33324, United States

Stuart Florida, 34994, United States

Tamarac Florida, 33321, United States

Chicago Illinois, 60611, United States

Chicago Illinois, 60612, United States

Chicago Illinois, 60612, United States

Chicago Illinois, 60637, United States

Indianapolis Indiana, 46202, United States

Iowa City Iowa, 52242, United States

Lexington Kentucky, 40536, United States

Louisville Kentucky, 40202, United States

Shrevport Louisiana, 71130, United States

Ann Arbor Michigan, 48109, United States

Grand Rapids Michigan, 49503, United States

Kalamazoo Michigan, 49007, United States

Kalamazoo Michigan, 49048, United States

Columbia Missouri, 65203, United States

St. Louis Missouri, 63141, United States

Neptune New Jersey, 07754, United States

Albuquerque New Mexico, 87109, United States

Bronx New York, 10466, United States

Buffalo New York, 14263, United States

New Hyde Park New York, 11040, United States

New York New York, 10019, United States

New York New York, 10032, United States

Valhalla New York, 10595, United States

Durham North Carolina, 27705, United States

Winston-Salem North Carolina, 27106, United States

Bismarck North Dakota, 58501, United States

Akron Ohio, 44302, United States

Canton Ohio, 44718, United States

Cincinnati Ohio, 45236, United States

Cleveland Ohio, 44195, United States

Oklahoma City Oklahoma, 72112, United States

Portland Oregon, 97201, United States

Hershey Pennsylvania, 17033, United States

Philadelphia Pennsylvania, 19104, United States

Philadelphia Pennsylvania, 19107, United States

Pittsburgh Pennsylvania, 15224, United States

Memphis Tennessee, 38120, United States

Nashville Tennessee, 37205, United States

Nashville Tennessee, 37232, United States

Houston Texas, 77030, United States

Temple Texas, 76508, United States

Arlington Virginia, 22205, United States

Richmond Virginia, 23298, United States

Charleston West Virginia, 25304, United States

Morgantown West Virginia, 26506, United States

Appleton Wisconsin, 54911, United States

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Estimated Enrollment:

500

Study ID:

NCT00161668

Recruitment Status:

Completed

Sponsor:


Wyeth is now a wholly owned subsidiary of Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider